If you’re a business owner, you know how challenging it can be to keep up with industry trends and customer demand. Luckily, there are many opportunities for entrepreneurs to leverage their expertise, invest in profitable ventures, and create strategic partnerships that help them grow their businesses. As new businesses launch and existing ventures expand this month, we want to ensure our readers are armed with the information they need to discover new opportunities. Here is a list of the best products and services related to healthcare equipment and supplies that you should buy in September if you want to expand your business.
Health care providers are increasingly using real-time continuous glucose monitoring (RT-CGM) to monitor their patients’ blood glucose levels and help them avoid hypoglycemia and hyperglycemia. DexCom’s stock has been up 50%+ since January, driven by strong demand for its RT-CGM products and continued adoption by healthcare providers. DexCom has raised its revenue guidance three times since the beginning of 2018, driven by higher-than-expected adoption of its CGM technology and higher-than-expected reimbursement rates. This trend is expected to continue, which makes DXCM an excellent investment for long-term growth. Investors can expect earnings growth of about 17% annually over the next few years, driven by solid demand for CGM technology and higher-than-expected growth rates. DXCM is currently trading at $67 a share, which is very cheap, given its strong growth potential. Buy DXCM if you’re looking for a long-term investment that will pay off as the healthcare industry increasingly relies on CGM technology.
Haemonetics is the leading company in the blood-cleaning device (BCD) market. The BCD device cleans blood stored in blood banks, hospitals, and blood donation centers. The BCD market is expected to grow as the population ages, leading to increased demand for blood transfusions. This growth is expected to be driven by introduction of new technologies for BCD devices that are more efficient, convenient, and cost-effective. Haemonetics’s stock is currently trading at $33 a share, down from a high of $40 in May. This price drop has created a great entry point for investors looking to buy HAE stock for long-term growth. Haemonetics’s earnings are expected to grow at about 16% annually over the next few years, driven by solid demand for BCD devices and product innovation. Investors can expect HAE stock to rise as BCD device demand grows and Haemonetics expands its product offerings to meet growing demand.
Steris’s Safety-Lok device prevents healthcare workers from contracting infectious diseases like hepatitis B, hepatitis C, and HIV. The Safety-Lok is a disposable device placed in gloves to create a barrier between healthcare workers and bloodborne pathogens. This device has been proven to reduce the risk of contracting bloodborne diseases by an average of 99%, making it one of the most effective ways to protect healthcare workers from potentially deadly diseases. Steris’s Safety-Lok device is currently being used in over 150 healthcare facilities across the United States, and the company expects to expand distribution to more facilities shortly. This growth is expected to be driven by the fact that healthcare regulatory agencies now require safety devices such as Steris’s Safety-Lok to be used in healthcare facilities. Steris’s stock currently trades at $30 a share, making it an excellent long-term investment, given its strong growth potential. Steris’s earnings are expected to grow at about 15% annually over the next few years, driven by safety-lok solid device adoption and increased operating efficiency.
Smith & Nephew (SNN)
Smith & Nephew is a leading medical device manufacturer that provides orthopedic, aesthetic, trauma, wound healing, and critical care products to hospitals and clinics worldwide. The company has experienced rapid growth as the global population ages, leading to an increased demand for medical services and products. Smith & Nephew is currently focusing on expanding its presence in Latin America, Asia, and the Middle East to meet growing demand in these markets. The company recently formed a joint venture with China’s most prominent orthopedic device manufacturer and has factories in Latin America and Southeast Asia. These investments have enabled the company to leverage its expertise in the industry to provide high-quality products and services to healthcare providers in these regions. Smith & Nephew is currently trading at $43 a share, a great price for investors looking to buy SNN stock for long-term growth. The company’s earnings are expected to grow at about 13% annually over the next few years, driven by strong demand for medical devices in emerging markets and product innovation.
When searching for a new product or service, you want to ensure it’s a strategic investment that will benefit your business in the long run. Make sure you research before purchasing, and don’t forget to factor in supplier quality and any potential distribution issues. If you choose the right product or service for your business, you can create strategic partnerships and leverage your expertise to grow your business and increase your profits.